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Increased  awareness  of  cancer  as  a health  crisis  facing  less  developed  healthcare  systems  has  led  to recent
calls  for  increased  investment  in  cancer  care  infrastructure  in low  resource  settings.  However,  opera-
tional  descriptions  of  well-functioning  cancer  care  systems  in resource-constrained  settings  are  limited.
AMPATH-Oncology  is  the  result  of  collaboration  between  North  American,  European,  and  Kenyan  part-
ners  to develop  a  comprehensive  cancer  care  model  that  supports  screening  services,  cancer  treatment,
and palliative  care.  This  article  describes  the  approach  taken  by  the  AMPATH-Oncology  program  to  deliver
cancer  care  in a resource-constrained  setting.  A  review  of  other  ‘high-income  –  low-income’  collaborativenternational
ealth care
reatment
IV/AIDS
rogram development
esearch
hemotherapy
models  identiﬁes  successful  strategies  to implement  cancer  care  in  low  resource  environments.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.ntroduction
In 2005, 60% of worldwide deaths were attributable to chronic
isease (cardiovascular disease, cancer, chronic lung disease, and
iabetes), and 80% of these deaths occurred in low and mid-
le income countries (LMICs) [1]. Chronic diseases affect younger
opulations in these settings, and cause longer suffering and a
igher loss of life-years than in high-income countries (HICs) [2,3].
ransitioning from a healthcare system designed to address acute
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Open access under CC BY-NC-ND lcare, to one engineered to tackle chronic care, is forcing health care
systems in LMICs to restructure and reallocate resources to prepare
for their changing healthcare needs [4]. This is a particular challenge
where governments spend 6% or less of their gross national budget
on healthcare [5]. Cancer care, as it is delivered in HICs, is one of the
most costly areas for healthcare delivery. In light of their economic
constraints, it is daunting to contemplate effectively addressing the
needs for comprehensive cancer care in LMICs. However, models for
the delivery of cancer care in under-resourced environments must
be developed to meet the rapidly growing need for these services.
Cancer already accounts for more deaths in the developing
world than tuberculosis, malaria, and HIV/AIDS combined [6]. In
2008, the American Cancer Society estimated that 56% of incident
cases and 64% of deaths due to cancer occurred in LMICs, and in
pediatrics, the numbers are even more skewed, with 80% of inci-
dent cases and deaths due to childhood cancers in LMICs [7]. Within
the next decade, global cancer rates are predicted to more than
icense.
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Table  1
Comparison of key economic and social indicators between Kenya and AMPATH-Oncology partner nations.
Country Kenya United States Canada The Netherlands
Population (millions) 39.8 298.6 34.5 16.7
Gross national income per capita (US$) 760 46,360 45,560 43,140
Infant mortality rate (per 1000 live births) 55 7 5 4
Life  expectancy at birth (years) 54 79 81 81
Health expenditure per capita (US$) 33 7410 5222 5593
Health expenditure (% of gross domestic product) 4.3 16.2 11 12
Out-of-pocket health expenditure (% of private expenditure on health) 77.4 24.2 50 38
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umbers reﬂective of 2009, 2010, or 2011 data.
ouble, but this burden will not be borne equally; death rates in
MICs are expected to be 5-fold higher than in HICs [8]. Within
he next two decades, shifts in habits (i.e. increases in smoking,
besity), transitions from rural to urban living, economic transi-
ion from an agricultural to industrial base, and aging populations,
ave led to predictions that 70% of all incident cancers will occur
n LMICs [9–11].
Cancer will also continue to rise in mortality tables for LMICs.
nlike HICs where the ratio of incidence to mortality is approxi-
ately one-third, 80% of patients diagnosed with cancer in LMICs
ill die of their disease [12]. It has been predicted that by 2030, 15%
f all deaths in LMICs will be attributable to cancer; 16% of those
eaths will occur in those under 70 years old; and these deaths
ill account for 7% of all the disability-adjusted life years (DALYs)
1]. The promulgation of guidelines and calls to action for cancer
esearch, prevention, and control in LMICs reﬂects awareness of
urrent needs and future demand [2,11,13,14].
However, implementation of cancer control strategies has
agged behind recommendations and guidelines, and there is only
imited published literature to guide programs in the development
f LMIC cancer programs. In prior publications we  have described
peciﬁc aspects of a cancer-care program being developed in west-
rn Kenya (i.e. cancer nursing skills [15], cancer pharmacy [16]).
erein, we present a more comprehensive picture of AMPATH-
ncology as a collaborative HIC-LMIC program that provides cancer
ervice in a resource-constrained setting that has delivered care to
housand of Kenyans.
he setting
By World Bank deﬁnitions, Kenya is a low-income country with
ver 39 million citizens and a gross national income per capita of
769 annually (2009 US dollars). Table 1 summarizes key indica-
ors for Kenya in comparison to the countries partnered in this
ancer care collaboration. In 2007/2008, the Government of Kenya
GoK) allocated 8.4% of its total national budget to health, trans-
ating into roughly $8.30 per capita annually spent on each citizen
6,17]. Kenya has a national health insurance plan available to all
itizens, the National Health Insurance Fund (NHIF), which covers a
ubstantial portion of in-patient hospital fees in governmental hos-
itals, but lacks coverage for outpatient services. Fees for enrolling
n NHIF range from less than US$2 per month to around US$25 per
onth, but fewer than 10% of the population is enrolled [18,19].
urther, enrollment in NHIF takes at least 2 months between enroll-
ent and initiation, a delay that frequently encompasses a critical
eriod for a newly diagnosed cancer patient.
The GoK recently passed a National Cancer Control Strategy to
e implemented between 2011 and 2016, but it is still too early
o deﬁne the impact this document will have on care for cancer
atients [20]. The existing infrastructure for cancer surveillance,
creening, and diagnosis is limited: two International Agency for
esearch in Cancer (IARC)-initiated regional cancer registries only
over a portion of the population; no national screening programsexist; limited diagnostics are available, both in terms of exper-
tise (i.e. pathologists, technologists, and radiologists) and resources
(pathology and radiology equipment). Even when a diagnosis of
cancer is possible, access to care is difﬁcult. The GoK recently deter-
mined there were only three medical/pediatric oncologists and four
radiation oncologists in the entire country, and just ﬁve of them
worked in the public sector [21]. In the public sector, there are two
cobalt-60 radiation oncology machines, both housed in Kenyatta
National Hospital (KNH) in Nairobi. Cancer drugs (chemothera-
peutics and supportive medications) are frequently unavailable in
governmental hospitals, and while they are available on the open
market, remain unaffordable to many.
A brief history of AMPATH and AMPATH-Oncology
Over the past decade AMPATH-Oncology evolved from an exist-
ing HIV program to meet the cancer care needs of western Kenya.
AMPATH-Oncology development occurred over four periods: a
limited pediatric cancer start-up; development of an AIDS-related
cancer agenda; rapid expansion into a chemotherapy-provision
program; and a period of strategic restructuring into the present
comprehensive care model. Programmatic growth has been driven
by Kenyan clinicians, with increasing service demands impelling
interactions between Kenyan clinicians and North American and
European oncologists. The foundational program for AMPATH-
Oncology, a locally initiated pediatric oncology program, provided
chemotherapy for child cancer patients funded by local businesses.
Care was  provided on the general pediatrics ward by one generalist
pediatrician and a nurse with limited additional training in pallia-
tive care and cancer nursing. However, with the remarkable growth
of the United States Agency for International Development – Aca-
demic Model Providing Access to Healthcare (USAID-AMPATH) HIV
treatment program, the needs for cancer care shifted.
USAID-AMPATH was created in 2001 through a collaboration
between Moi  University School of Medicine (MUSM;  the second
medical school in Kenya), Moi  Teaching and Referral Hospital
(MTRH; the second governmental tertiary referral hospital in
Kenya), and a consortium of North American academic medical
centers to combat HIV/AIDS in western Kenya [22]. Utilizing the
expertise of MUSM faculty and North American academic physi-
cians, combined with the clinical facilities and personnel of MTRH,
USAID-AMPATH developed a successful model for HIV/AIDS treat-
ment which currently delivers care to over 140,000 patients with
2000 new patients enrolling monthly [23,24]. With the provision
of anti-retroviral therapy, however, clinicians faced patients devel-
oping HIV/AIDS-associated malignancies (e.g. Kaposi’s sarcoma,
non-Hodgkin’s lymphoma).
In order to address this new patient population, AMPATH-
Oncology developed from the pediatric cancer program into an
HIV malignancies program, increasing the number of nurses and
clinicians and incorporating the expertise of North American med-
ical oncologists. This marked the transition from a small local
effort addressing speciﬁcally pediatric cancers into a HIC-LMIC
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Table  2
Infrastructure developed by USAID-AMPATH repurposed for cancer care.
• NIH-certiﬁed grants management ofﬁce with existing procedures for
transparent transfer and utilization of funds in Kenya
• Educational institute facile in arranging short- and medium-term
training workshops
• Good Clinical and Laboratory Practices (GCLP) and ISO 9000-certiﬁed
clinical laboratory, as well more limited clinical laboratory facilities in
remote clinic sites
•  Motor pool with maintained vehicles, and network of transportation to
move clinical personnel remotely and remote patients to higher-level
care facilities
• An informatics development and support group, the primary product of
which is an open-source electronic medical record system, AMRS
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Table 3
Current organization and services of AMPATH-Oncology.
Theme Present activities Planned activities
Screening and
prevention
• Breast cancer screening
• Cervical cancer screening
• Immunization campaigns
• Anti-smoking campaign
Diagnosis and
treatment
• Immunohistochemistry
• Medical oncology services
•  Gynecology oncology
services
•  Pediatric oncology
services
• Radiation oncology
• Tissue bank
Palliative care • Palliative care outpatient
clinic
• Coordination of hospice
services[56,57,58,59]
• An existing monitoring and evaluation program
ollaborative cancer project with the objective of treating
IDS-related malignancies. However, once cancer diagnosis and
reatment infrastructure was in place patients began to present
ith non-AIDS-related cancers, forcing the program to expand its
cope. The rapid growth in patient population threatened to out-
trip the available personnel and resources, forcing the nascent
ancer care services to move away from a program simply providing
hemotherapy into program managing cancer patients through-
ut their disease course. The present AMPATH-Oncology program
eveloped out of the need to implement resource-conscious
ystem-wide improvements while delivering comprehensive can-
er care.
xtending care: a cancer care program created from
xisting resources
The cancer care program was built on the backbone of the
xtant infrastructure that was developed to address the HIV pan-
emic. USAID-AMPATH superstructure, a hub-and-spoke model of
are delivery developed to increase accessibility of services to an
mpoverished rural population, was repurposed to address cancer
25]. More than 50 remote sites, housed in GoK Ministry of Med-
cal Services (MoMS) facilities ranging from permanent buildings
ith reliable electricity and in-house laboratory services to basic
linical venues – at times, a simple tent in a ﬁeld – serve as a dis-
ributed, accessible network for population-based cancer screening
nd prevention activities [26]. This network also has processes in
lace for referral of more complex cancer cases to the higher-level
are centers, and facilitates adequate follow-up. The transporta-
ion and communication schema serving the HIV/AIDS network
unnels patients to more resourced sites that offer cancer care,
nd can move cancer personnel out to the village. Additional key
esources developed by USAID-AMPATH that support the cancer
are program are outlined in Table 2.
USAID-AMPATH’s existing relationship with the GoK facili-
ated targeted, cost-effective governmental involvement via MTRH
n support of the development of cancer services. Through cre-
tion of the MTRH Department of Hematology & Oncology, onto
hich AMPATH-Oncology was overlaid, the MoMS  shares clinical
nfrastructure and personnel costs. Critically, this frees non-
overnmental funds for targeted infrastructure development and
ersonnel training. Ministry employees assigned to the department
nclude administrative staff, pharmacy technicians, nursing, clinical
fﬁcers, medical ofﬁcers, and physicians. This also allows dedicated
pace for oncology including: outpatient clinic space (shared with
ther USAID-AMPATH chronic disease programs); a chemother-
py pharmacy; chemotherapy administration areas; and a pediatric
n-patient oncology unit.
To efﬁciently utilize limited personnel and resources, the
linical services of AMPATH-Oncology are supported by a core• Palliative care in-patient
consult service
infrastructure comprised of a cancer registry, a cancer nursing
service, a chemotherapy pharmacy service, administration (tasked
with scheduling, educational development, and programmatic
monitoring and evaluation), and research support (responsible
for data management, institutional review liaison, research assis-
tants). The cancer registry, established by IARC in the early 1990s,
required additional investment to support the personnel to update
the registry, improve stability of the information storage, and re-
evaluate quality controls in registry data. The ﬁrst two projects
were addressed by hiring registry personnel and investing in new
hardware. The latter project, a work in progress, is using pro-
grammatic mentoring between North American registries and the
Eldoret Cancer Registry to supplement ongoing support by IARC.
While nursing and pharmacy services were eager to engage in
cancer care initiatives, neither service had personnel with speciﬁc
training in cancer care or chemotherapy. Therefore, an agreement
was  made with MTRH nursing and pharmacy administration to
train speciﬁc personnel in the care of cancer patients, safe hand-
ling and administration of chemotherapeutics, and supportive care.
These personnel were trained through short-term, on-ground edu-
cational programs created by North American oncology nurses
and clinical pharmacists who  had spent time working with these
nurses to identify current practice areas in need of improvement.
In developing these workshops it was critical to work with experts
who  could spend time on-ground so that educational objectives
could be framed within the constraints of the practice environment.
Ongoing educational programs focusing on pediatric oncology have
been facilitated both in Kenya and Amsterdam through the Doc-
tor2Doctor collaboration between VU University Medical Center
(VUmc), KLM Healthcare and MTRH.
Finally, recognizing that cancer care in resource-constrained
settings lacks an evidence base to guide decisions, AMPATH-
Oncology developed a core service to support research. Coordinat-
ing with the existing resources within AMPATH (an NIH-certiﬁed
institutional review board, an AMPATH research coordination
ofﬁce, a large data management infrastructure), AMPATH-
Oncology hired research assistants and data managers to help
maintain databases and work with the larger AMPATH research
agenda. Presently, this group is supporting both health services
research as well as clinical trials and translational studies to help
deﬁne cancer in Kenya, with rapid feedback of local outcomes to
inform the development of care strategies. Additionally, strategic
investments have been made to improve the diagnostic capabili-
ties of MTRH, with the coordination of expertise and resources to
improve the reliability of pathologic diagnosis and creation of an
immunohistochemistry laboratory.Supported by these core services, AMPATH-Oncology is divided
into three major organizational structures: Screening & Prevention;
Diagnosis & Treatment; and Palliative Care. Table 3 summarizes
the current and planned activities of each administrative group.
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Table  4
Cancer categorization for resource allocation and treatment protocols.
Priority High Medium Low
Criteria • Curative intent • Palliative
•  High RR
• Long PFI
•  Palliative
•  Low RR
•  Short PFI
Examples • Pediatric acute
leukemias and
lymphomas
• Locally advanced
breast cancer
• Kaposi’s sarcoma
•  Ovarian cancer
•  Metastatic breast
cancer
• Pancreatic cancer
• Gastric cancer
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Table 5
Programmatic indicators for AMPATH-Oncology.
Cervical screening Breast screening
Prevention and screeninga
Number screened 17,651 3699
Pre-malignant lesions identiﬁed 476b N/A
Cancer identiﬁed 347 50
Pediatric oncology Gynecologic oncology Adult oncology
Diagnosis and treatmentc
Top diagnoses (number of patients)
SCD (100) CC (250) KS (230)
ALL (35) OVC (64) BRCA (200)
NHL (26), RTB (22) ENDO (24), VC (8) HL (77)
Palliative carec
Number of patients under treatment 1020
Liters of morphine dispensed 98
Abbreviations: SCD, sickle cell disease; ALL, acute lymphoblastic leukemia; NHL,
non-Hodgkin’s lymphoma; RTB, retinoblastoma; CC, cervical cancer; OVC, ovarian
cancer; ENDO, endometrial cancer; VC, vulvar cancer; KS, Kaposi’s sarcoma; BRCA,
breast cancer; HL, Hodgkin’s lymphoma.
ment [36]. Collaborative training to increase the workforce andbbreviations: RR, response rate; PFI, progression free interval.
he ﬁrst, and most established services (Medical, Pediatric, and
ynecologic Oncology), were initially developed to provide safe
hemotherapy delivery, but have evolved over time to encompass
ther aspects of active care, including limited diagnostics (i.e. punch
iopsy service for Kaposi’s sarcoma) and surgical services in gyne-
ologic oncology. With each of these treatment-oriented groups, an
arly effort was made to rationalize treatment based on balancing
imited budgets and limited availability of drugs against the need
o optimize beneﬁts.
Using the essential drugs for cancer therapy list published by
he WHO  as a starting point, North American and Kenyan clinicians
eviewed the local epidemiology and weighed clinical beneﬁt of
otential regimens against cost [27]. A rank-ordered list of diseases
as created using a categorization schema prioritizing: curative
herapy above palliative; in palliative settings, longer progression
ree intervals over shorter; and, cheaper over more expensive regi-
ens. This list was subsequently used to dictate treatment patterns
nd fund allocation for chemotherapy. Table 4 presents a selection
f this prioritization schema.
With development of standardized protocols for chemotherapy
elivery and deﬁnition of patient groups for whom chemotherapy
as not indicated (i.e. advanced cancers with limited beneﬁt for
hemotherapy), development of a palliative care service was  crit-
cal both for cancer patients, but also for cancer care providers
 who frequently felt that not being able to provide chemother-
py equated to not being able to provide care. Providing surgery,
hemotherapy, and palliative services enabled AMPATH-Oncology
o move into active case detection and preventative services. In
 resource-limited setting, most screening activities identify not
nly pre-malignant conditions, but also relatively advanced can-
ers. Having the possibility of treatment made population-based
creening acceptable to both the medical providers and the com-
unity at-large.
There are insufﬁcient physicians trained in oncology to provide
hese services, therefore AMPATH-Oncology has relied heavily on
lternative models of care. Palliative care is a nurse-driven service,
s are the breast and cervical screening programs, in which nurses
ave been trained in clinical breast exam, cervical visual inspection
nder acetic acid (VIA), and cryotherapy. Cancer care is delivered
y tiered service-providers – the limited physicians see complex
ases, but physician extenders deliver routine care and follow-up.
he less experienced providers are supported by explicit proto-
ols, which address resource-appropriate diagnostics, standardized
and ﬂat-dosed) chemotherapy regimens, and clear start-stop rules.
inally, program-wide guidelines, recognizing the ﬁnite program
esources, deﬁne limits to the care AMPATH-Oncology will deliver,
ut temper these limits with a robust palliative care program.
With this organizational structure AMPATH-Oncology has been
ble to deliver reasonably comprehensive cancer care. To date,
MPATH-Oncology has provided care to over 30,000 patient visits
etween screening services, the 4 clinical services, and an in-
atient consultation service. Screening services include clinicala Reﬂective of service inception to December 2012.
b Inclusive of CIN I, II, and III.
c Reﬂective of December 2011 to December 2012.
breast exam with facilitated FNA biopsies, as needed, and a cer-
vical cancer screening service using visual inspection under acetic
acid in a “screen and treat” model using cryotherapy (although col-
poscopy and loop excision and appropriate surgical services are
available as needed). Delivery of chemotherapy, both in-patient and
out-patient, is a major role of AMPATH-Oncology, but consultation
individually and through multi-disciplinary tumor boards serve key
roles in improving outcomes in cancer patients. The programmatic
indicators are presented in Table 5.
Discussion
Literature documenting successful implementation of resource-
constrained cancer care programs created through HIC-LMIC
collaborations is limited. The best documented are those of the
Monzas International School of Pediatric Hematology/Oncology
(MISPHO, Italy), the St. Jude International Oncology Program (Mem-
phis, USA), the VU University Medical Center in Amsterdam (VUmc
– The Netherlands), and the Ethiopia Breast Cancer Project (EBCP).
St. Jude and MISPHO have published extensively on nursing edu-
cation, program development, and outcomes – but are limited in
scope to pediatric oncology and are geographically centered in Latin
America [28–31]. Similarly, VUmc’s work is focused on pediatric
oncology and in a fairly dissimilar setting [32–34]. The EBCP has
documented strategies, successes, and challenges of developing a
breast cancer program in Ethiopia – however, while the Ethiopian
healthcare system similar to the Kenyan system, this program is ori-
ented to a single disease [4,35–37]. AMPATH-Oncology represents
a comprehensive approach to cancer care in a resource-constrained
setting. However, similarities between these programs identify
themes to successful implementation of HIC-LMIC collaborations
for cancer care.
Access to cancer therapy in LMICs is limited [38]. However,
cancer care in HIC-LMIC collaborations is not simply about donat-
ing drugs. Indeed, it might be judged irresponsible to simply
increase access (and often sporadic supplies) of therapeutics that
have narrow therapeutic margins and large potential to inﬂict
harm on patients without investing in local capacity develop-creation of standardized protocols is a critical ﬁrst step. Combin-
ing LMIC process expertise (i.e. how to get something done in a
resource-constrained setting) with HIC content expertise (deﬁning
e ancer
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n international gold standard for a given cancer) offers the oppor-
unity to develop locally appropriate standardized protocols and
 baseline standard of care. Implementation of this standard cre-
tes locally relevant outcomes data against which new efforts can
e compared. Additionally, protocols compensate for differences in
ractitioner education and levels of clinical experience with cancer
reatment, giving increased safety margins to task shifting. Finally,
hese protocols can be designed to facilitate system-wide demand
ssessment, efﬁciency in ordering, and waste reduction.
Protocols must balance local feasibility against best-practices
39–41]. Treatment of cancer in HICs has evolved to progressively
ore complex chemotherapy regimens with higher rates of tox-
city. However, toxicity is not as well tolerated in systems with
nadequate access to supportive services (i.e. poor blood transfu-
ion capabilities, lack of antibiotics), and can lead to unexpectedly
igh morbidity and mortality in resource-constrained settings [42].
herefore, it is critical to focus on developing appropriate care mod-
ls for the available resources, an approach best exempliﬁed by the
ecommendations of the Breast Health Global Initiative’s “resource-
tratiﬁed matrix” approach [43].
To support the implementation of protocols in LMICs there must
e investment in skill development and infrastructure to deliver
ancer care. Cancer specialists at all levels of health care deliv-
ry in LMICs are rare. As previously noted, Kenya reports only ﬁve
ublic sector cancer physicians, or one oncologist to roughly 7 mil-
ion population, therefore task shifting is required to meet patient
emand for cancer services. In Kenya, the physician is typically
esponsible for the preparation and administration of chemothera-
eutics – both of which are time-intensive duties. Dividing tasks
nto the domain of pharmacy personnel and nursing staff helps
nsure both task-speciﬁc expertise and frees clinicians to utilize
heir expertise in patient management. Task shifting, however,
ust be done in conjunction with training and explicit care pro-
ocols [27,36].
Recognition of patient-level, as opposed to system-level, limita-
ions is also critical to delivery of cancer care. MISPHO, recognizing
reatment abandonment as a point of failure in pediatric cancer
are delivery, has developed patient-family hostels, transport fees,
nd other innovative approaches to reduce barriers of access to
are [30,44]. Similarly, VUmc has focused on parental education
o increase patient retention [45]. The EBCP has published focus
roup analyses offering insight on barriers to patient utilization of
heir program [46]. AMPATH-Oncology, with its distributed net-
ork of care delivery, is able to make use both of the remote clinics
o deliver care and the transport infrastructure already in place to
acilitate patient referrals to a centralized care site. Nonetheless,
ur experience resembles those described in Sri Lanka, in which
ravel to cancer services can be up to a two day journey – although
n our case it is by mini-bus as opposed to train – and remains an
rea in need of development [47]. Treatment abandonment, rare in
ICs, remains a signiﬁcant source of mortality for cancer patients
n LMICs – further research is needed to develop abandonment
eduction strategies.
Finally, these successful HIC-LMIC collaborations have clearly
eﬁned research as integral to their care delivery systems. Trial
ata on treatment and outcomes for cancer patients in LMICs are
parse [48–50]. While generating LMIC-speciﬁc trials is impor-
ant, it is equally important to ﬁll in our understanding of current
tandards of care. In LMICs access to antibiotics, transfusions,
nd other supportive care measures readily available in HICs is
ot guaranteed, therefore outcomes in LMICs at current stan-
ards of care may  be less than expectations generated by trials
ata, and routine care outcomes must be deﬁned [51,52]. All
f these collaborations recognize this implicitly and have built
ystems to analyze outcomes in the context of routine clinical
are. Policy 1 (2013) e42– e48
Conclusion
Success of AMPATH-Oncology has led to growth in referrals
from western Kenya and beyond, which has necessitated rationing
of care to focus limited resources on those patients expected to
have best outcomes, and implementation of fee schedules to offset
costs. This programmatic growth has outgrown the infrastructure
of AMPATH and MTRH – ground has been broken for a new build-
ing to house cancer care. Additionally, there are still gaps in the
care AMPATH-Oncology can deliver because of missing vital infra-
structure – there is no radiation oncology. KNH and the Uganda
Cancer Institute, in Kampala, Uganda, are the closest sites for radi-
ation therapy, each many hours to days away. In order to address
this, AMPATH-Oncology is working with the IAEA, the GoK, donors,
and radiation equipment manufacturers to create a second hub for
radiation therapy in Kenya.
Use of existing infrastructure, coordination with GoK  health-
care, treatment protocols developed around affordable off-patent
chemotherapeutics, and task-shifting have allowed AMPATH-
Oncology to provide services in a cost-conscious manner. Presently,
AMPATH-Oncology services 10–15,000 patient visits a year at a
cost of US$750,000 generated through research and service grants.
Much of this investment has been in training and infrastruc-
ture, both of which offer durable returns. AMPATH-Oncology’s
chemotherapy is not expensive, certainly not by American stan-
dards, and is likely similarly cost-effective as other AMPATH
programs [53]. However, chemotherapy remains a major program-
matic budget-line – one that will continue to grow in an unsus-
tainable manner as the patient population continues to increase.
AMPATH-Oncology is one solution for cancer care in LMICs, and
has managed to provide extensive service to a large population at a
low initial cost. However, it remains an area of active research and
thought to ﬁnd sustainable methods to maintain these services.
Mutual trust, shared decision-making, local ownership, pro-
grammatic evaluation and feedback leading to practice changes,
and development of local capacity have been proposed as guiding
principles for HIC-LMIC collaborative cancer research projects [54].
The principles have guided the development and organizational
structure of AMPATH-Oncology and other successful HIC-LMIC
care-driven collaborations. One of the fundamental differences
between HIV care and cancer care is the large additional infra-
structure necessary to prevent, diagnose, and treat cancer patients
[55]. AMPATH-Oncology’s development of comprehensive services
was  driven by connecting multiple components of a healthcare sys-
tem to deliver appropriate care. It is from these principles that
AMPATH-Oncology will continue to offer care while exploring solu-
tions to deliver sustainable comprehensive care for cancer patients
in western Kenya.
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